| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
DNA Ligase IV; CRISPR/Cas9
|
|---|---|
| ln Vitro |
SCR7 pyrazine (20-100 μM; 24 hours; MCF7 cells) treatment causes unrepaired double-strand breaks (DSBs) to accumulate in cells by interfering with NHEJ[1].
SCR7 pyrazine treatment results in a dose-dependent reduction in cell proliferation, with IC50 values for MCF7, A549, HeLa, T47D, A2780, HT1080, and Nalm6 cells, respectively, of 40 μM, 34 μM, 44 μM, 8.5 μM, 120 μM, 10 μM, and 50 μM[1]. SCR7 pyrazine (20, 40 μM) treatment of MCF7 cells results in increased phosphorylation of ATM and activates p53, while decreasing MDM2, BCL2, and activating proapoptotic proteins, PUMA and BAX. Furthermore, there is a dose-dependent increase in the cleavage of the shorter fragments of MCL1, PARP1, Caspase 3, and Caspase 9[1]. |
| ln Vivo |
SCR7 pyrazine (10 mg/kg; intraperitoneal injection; six doses; BALB/c mice) treatment lengthens life expectancy and significantly reduces tumors caused by breast adenocarcinoma[1].
|
| Cell Assay |
Cell Line: MCF7 cells
Concentration: 20 μM, 40 μM, 100 μM Incubation Time: 24 hours Result: Showed an increase in levels of gH2AX foci and protein. |
| Animal Protocol |
BALB/c mice injected with breast adenocarcinoma cells
10 mg/kg Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10) |
| References |
| Molecular Formula |
C18H12N4OS
|
|---|---|
| Molecular Weight |
332.38
|
| Exact Mass |
332.073
|
| Elemental Analysis |
C, 65.05; H, 3.64; N, 16.86; O, 4.81; S, 9.65
|
| CAS # |
14892-97-8
|
| Related CAS # |
14892-97-8
|
| PubChem CID |
10688007
|
| Appearance |
Light yellow to yellow solid powder
|
| Melting Point |
209 °C
|
| LogP |
3.748
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
487
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S=C1N([H])C(C2=C(N1[H])N=C(C1C([H])=C([H])C([H])=C([H])C=1[H])C(C1C([H])=C([H])C([H])=C([H])C=1[H])=N2)=O
|
| InChi Key |
GSRTWXVBHGOUBU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H12N4OS/c23-17-15-16(21-18(24)22-17)20-14(12-9-5-2-6-10-12)13(19-15)11-7-3-1-4-8-11/h1-10H,(H2,20,21,22,23,24)
|
| Chemical Name |
6,7-diphenyl-2-sulfanylidene-1H-pteridin-4-one
|
| Synonyms |
SCR-7 pyrazine; SCR7 pyrazine; SCR 7 pyrazine
|
| HS Tariff Code |
2933598000
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~66 mg/mL (~198.6 mM)
Ethanol: ~23 mg/mL (~69.2 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0086 mL | 15.0430 mL | 30.0860 mL | |
| 5 mM | 0.6017 mL | 3.0086 mL | 6.0172 mL | |
| 10 mM | 0.3009 mL | 1.5043 mL | 3.0086 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA